Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy -- Ignore unavailable to you. Want to Upgrade?

To: Richard Haugland who wrote (122)	6/15/1998 5:11:00 PM
From: Richard Haugland	Read Replies (2) \| Respond to of 184

SangStat Receives CYCLOSPORINE US Patent Covers Multiple Formulations Including Sang-35 biz.yahoo.com Released after market closed Cyclosporine is the leading immunosuppressive drug used in transplantation to prevent graft rejection. Cyclosporine is marketed by Novartis Ltd. in different formulations as Sandimmune(R) and Neoral with estimated worldwide sales of $1.3 billion in 1997. Subject to FDA approval, Sang-35 is expected to compete with Sandimmune and Neoral. In the U.S. and Europe there are more than 200,000 transplant recipients requiring daily immunosuppressive therapy for the rest of their lives, the majority of whom take cyclosporine. Novartis' composition of matter patent on cyclosporine expired in the U.S. in September, 1995.